GlassScriptPhysician profile
Kimberly Robertson
NPI 1124427133
$1,382.87
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.56 · 2022: $138 · 2023: $917 · 2024: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $395.60 | 2023-2024 | Provenge |
| Sumitomo Pharma America, INC. | $322.47 | 2023-2024 | Gemtesa, Orgovyx |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $123.50 | 2022 | |
| Janssen Biotech, INC. | $73.06 | 2023-2024 | Erleada |
| Abbvie INC. | $45.21 | 2023-2024 | |
| Urogen Pharma, INC. | $43.89 | 2024 | |
| Tolmar, INC. | $41.78 | 2023 | |
| Genentech USA, INC. | $37.48 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $37.33 | 2023-2024 | Prolaris |
| Endo Pharmaceuticals INC. | $34.59 | 2023 | Xiaflex, Aveed |
| Verity Pharmaceuticals INC. | $30.73 | 2023 | Trelstar |
| Bayer Healthcare Pharmaceuticals INC. | $19.97 | 2023 | |
| Merck Sharp & Dohme LLC | $19.61 | 2023 | Lynparza |
| Astellas Pharma US INC | $16.33 | 2024 | Xtandi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $16.32 | 2023 | Infyna Chic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.